Nucleic acids and polypeptides
OwnerJohn P. Carulli, Alexander V. Lukashin +2inventors
InventorsJohn P. Carulli, Alexander V. Lukashin, Daniel R. Kilburn, Punam Mathur
Life of this patent
Estimating the term…
Abstract
An isolated polynucleotide encoding a novel immunoglobulin superfamily member named GP286 is provided. GP286 has a predicted single membrane spanning domain and one immunoglobulin (Ig) domain in the extracellular portion of the protein. The protein structure and tissue distribution of GP286 indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the immune system. Provided by the invention are isolated GP286 related polynucleotides and polypeptides, vectors, and host cells comprising any of the above, antibodies directed to GP286, cells which produce such antibodies, and related diagnostic and therapeutic methods.
Claims53
An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
- (a) SEQ ID NO:
- 1, and allelic variants thereof;
- (b) a fragment of (a), consisting of at least 17 nucleotides;
- (c) a nucleotide sequence that encodes SEQ ID NO:2, an allelic variant thereof or fragments of either consisting of at least six amino acid residues;
- (d) a nucleotide sequence that is at least 65% identical to SEQ ID NO:
- 1;
- (e) a nucleotide sequence that encodes a protein that is at least 80% homologous to SEQ ID NO:2;
- (f) a nucleotide sequence that hybridizes to SEQ ID NO:
- 1 under high stringency conditions;
- and
- (g) a complementary sequence of any of (a) through (f);
- (h) SEQ ID NO:
- 14, and allelic variants thereof
- (i) a fragment of (h), consisting of at least 17 nucleotides;
- (j) a nucleotide sequence that encodes SEQ ID NO:
- 15, an allelic variant thereof or fragments of either consisting of at least six amino acid residues;
- (j) a nucleotide sequence that is at least 65% identical to SEQ ID NO:14;
- (l) a nucleotide sequence that encodes a protein that is at least 80% homologous to SEQ ID NO:15;
- (m) a nucleotide sequence that hybridizes to SEQ ID NO:
- 14 under high stringency conditions;
- and
- (n) a complementary sequence of any of (h) through (m).
A method of identifying a compound that binds a GP286 protein, comprising the steps of:
- contacting a GP286 protein with a test compound;
- and
- detecting a complex formed by said GP286 protein and said test compound, wherein the presence of said complex indicates that said test compound binds to said GP286 protein.
A method of identifying a compound that modulates the activity of a GP286 protein, comprising the steps of:
- contacting said GP286 protein with a test compound;
- and
- determining the effect of the test compound on the activity of said GP286 protein, whereas a change of said activity after the contacting step indicates that said test compound modulates the activity of said GP286 protein.
A method of identifying a homolog of a human gp286 gene, comprising the steps of screening a nucleotide database with a query sequence consisting of SEQ ID NO:1 or SEQ ID NO:14 or a portion of SEQ ID NO:1 or SEQ ID NO:14 consisting of 300 or more nucleotides,
- wherein a nucleotide sequence in said database that is at least 65% but less than 100% identical to SEQ ID NO:
- 1 or SEQ ID NO:
- 14 or said portion of SEQ ID NO:1 or SEQ ID NO:
- 14, if found, is a homolog of a human gp286 gene.
A method of identifying a homolog of a human gp286 gene, comprising the steps of:
- hybridizing a polynucleotide library with a polynucleotide probe under high stringency hybridization conditions comprising SEQ ID NO:1 or SEQ ID NO:14, or a portion of SEQ ID NO:1 or SEQ ID NO:14 consisting of at least 17 nucleotides;
- and
- determining whether said polynucleotide probe hybridizes to a polynucleotide in the library,
- wherein the polynucleotide so hybridized is a homolog of a human gp286 gene.
A method of diagnosing a disease condition in a subject, comprising the step of comparing the amount or activity of a GP286 protein in a tissue sample from said subject to the amount or activity of the GP286 polypeptide in a control sample,
- wherein a significant difference in the amount or activity of said GP286 polypeptide in said tissue sample relative to the amount or activity of said GP286 polypeptide in said control sample indicates that the subject has a disease condition.
A method of diagnosing a disease condition in a subject, comprising the step of comparing the amount of a gp286 mRNA in a tissue sample from the subject to the amount of said gp286 mRNA in a control sample,
- wherein a significant difference in the amount of said mRNA in said tissue sample relative to the amount of said mRNA in said control sample indicates that the subject has a disease condition.
A diagnostic assay for identifying in a test cell the presence or absence of a genetic lesion or mutation characterized by at least one of:
- (i) aberrant modification or mutation of a gene encoding a GP286 protein;
- (ii) mis-regulation of a gene encoding a GP286 protein;
- and (iii) aberrant post-translational modification of a GP286 protein;
- comprising the steps of
- separately hybridizing polynucleotides from the test cell and from a reference cell that lacks said genetic lesion or mutation with a polynucleotide probe comprising SEQ ID NO:
- 1, SEQ ID NO:
- 14 or a portion thereof consisting of at least 17 nucleotides, under high stringency hybridization conditions;
- and
- separately washing said polynucleotide hybrids under high stringency wash conditions to allow dissociation of the hybrids;
- and
- determining whether said polynucleotide probe dissociates more readily from the polynucleotides of the test cell compared to the polynucleotides of the reference cell.
Dependencies are inferred from the claim text.